Rahul Singhvi is an Operating Partner at Flagship Pioneering. At Flagship Pioneering, Rahul is responsible for operating young start-up companies launched from Flagship’s innovation foundry, Flagship Labs.
Prior to Flagship, Rahul was the Chief Operating Officer at Takeda’s Vaccine Business Unit where he was responsible for global vaccine operations at the Takeda Pharmaceutical Company. During his six-year tenure at Takeda, the vaccine business grew to over 500 employees and created an impressive late stage pipeline of vaccine candidates against dengue, norovirus, and zika. Before joining Takeda, Rahul was President and CEO of Novavax, Inc. (NASDAQ: NVAX), a clinical stage vaccine company. Under Rahul’s leadership, Novavax transformed from a failed specialty pharmaceutical business to a vaccine development company with vaccine candidates against influenza (funded by BARDA) and respiratory syncytial virus (RSV). Rahul’s professional career began at Merck & Co in 1994, where he held several positions in R&D and manufacturing.
Rahul Singhvi serves on the Executive Advisory Board of the Leonard Davis Institute (LDI) of Health Economics at the University of Pennsylvania and as an advisor to the Office of Technology Transfer at the University of Maryland, Baltimore. He is a mentor instructor in the Undergraduate Projects Opportunity Program (UPOP) at MIT. He serves as a visiting lecturer at the University College London (UCL) and is also on the faculty of the University of Sienna’s Master’s course on Vaccinology.
Rahul graduated as the top ranked chemical engineer from IIT, Kanpur, India and obtained both his M.S. and Sc.D. chemical engineering degrees from MIT. He received an M.B.A. from the Wharton School of the University of Pennsylvania, where he graduated as a Palmer Scholar.